Benitec Biopharma is engaged in providing a treatment from a single administration using DNA-directed RNA interference (ddRNAi). DdRNAi is being used to develop a pipeline of product candidates for the treatment of chronic and life-threatening human diseases. As of June 30, 2016, Co. has three pipeline programs in development: Hepatitis B BB-HB-331 for the treatment of hepatitis B; Age-related macular degeneration (AMD) program that provides treatment of AMD from a single intravitreal injection, and Oculopharyngeal Muscular Dystrophy, which is an autosomal-dominant inherited, slow progressing, late-onset degenerative muscle disorder that usually starts in patients during their 40s and 50s.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.